摘要
重组蛋白药物经静脉和皮下注射后通常半衰期较短,目前延长蛋白药物半衰期的方法主要基于三种原理:1、增大蛋白药物分子量;2、利用血浆药物平衡;3、减少免疫原性。针对构建突变体、PEG化修饰和与血清白蛋白融合三种延长重组蛋白药物半衰期的方法,及其已上市的和正在研发中的长效重组蛋白药物的特征、半衰期和免疫原性问题进行了综述。
The recombinant protein drug usually has a short half-life after intravenous （IV） or subcutaneous （SC） administration. The methods of prolonging the half-life of recombinant protein drug in common use are mainly based on three principles： 1 Amplifying the molecule weight of protein drug; 2 Making use of drug balance in the blood; 3 Reducing Immunogenicity. Three methods were focused on： Analog construction, PEGylation and Albumin fusion technology. The characteristics, half-life and immunogenicity problem of their products in the market and under development are summarized.
出处
《中国生物工程杂志》
CAS
CSCD
北大核心
2006年第2期79-82,共4页
China Biotechnology
